QUEST DIAGNOSTICS INC News
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
see moreQUEST DIAGNOSTICS INC Market News
13d
Quest Diagnostics Q4 Beat Lifts DGX Shares 15% YTD
- Quest Diagnostics reported a Q4 revenue and EPS beat with raised 2026 guidance, driving a double-digit surge in DGX shares. The results reflect stronger test volumes, higher-value diagnostics, and improved margins—key near-term catalysts for investors.
20d
Quest Diagnostics Q4 Beat AI Companion Fuels Rally
Quest Diagnostics (DGX) posted a strong Q4, raised 2026 guidance, expanded shareholder returns and launched the Quest AI Companion—moves that underpinned a double-digit stock rally and signal a tighter focus on consumer engagement and strategic growth.
27d
DGX Upside: AI Tool Launch and Medicare Relief
Recent concrete developments for Quest Diagnostics (DGX) — the launch of a Gemini-powered Quest AI Companion, a one-year delay to PAMA/CLFS Medicare cuts, and clarified CMS reporting guidance — together provide short-term revenue protection and a digital differentiation that could support DGX's operational resilience and investor outlook.
16 Mar at 04:27
Quest Diagnostics: Corewell JV Boosts DGX Value Q1
Quest Diagnostics finalized a 51/49 joint venture with Corewell Health to operate Diagnostic Lab of Michigan, rolling out Collaborative Lab Solutions across 21 hospitals and planning a 100,000 sq ft lab for Q1 2027. The transaction strengthens DGX’s regional scale and recurring revenue potential while underscoring the need to monitor reimbursement pressures and execution of productivity initiatives.
09 Mar at 04:27
Quest Diagnostics Clears LDT Risk — Stock Up Today
Quest Diagnostics (DGX) received a near-term regulatory relief after a court vacated the FDA's proposed oversight of laboratory-developed tests (LDTs) and the agency declined to appeal. Coupled with a recent earnings beat, raised guidance, a dividend increase and a $1B buyback, DGX shares have climbed sharply. Parallel industry trends—especially AI-driven claims automation—offer structural tailwinds that could improve reimbursement efficiency for diagnostic labs.
02 Mar at 04:27
Quest Diagnostics Surges: MRD Test, Dividend Boost
Quest Diagnostics (DGX) posted strong Q4 results, introduced a blood-based MRD test for multiple myeloma, and announced a meaningful dividend increase plus a $1 billion buyback authorization. These concrete developments strengthen DGX’s growth and shareholder-return thesis, while Medicare reimbursement pressure and ongoing IT modernization remain key operational factors to monitor.
23 Feb at 04:27
DGX: Beat, Dividend Hike, Medicare Cut Risk Ahead.
Quest Diagnostics (DGX) reported a Q4 beat, raised 2026 guidance, boosted its dividend and expanded buybacks—sparking a notable share gain—while looming Medicare reimbursement cuts for hundreds of lab tests create a tangible near-term policy risk.